NoCUT-BCNCT07217990
Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer
At risk: Primary completion moved 31 days later.
See at-risk trials from Ohio State University Comprehensive Cancer Center
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Start date: Sep 15, 2026 to Jan 15, 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 38 words
- Primary and study completion pushed from Dec 31, 2027 to Jan 31, 2028
- Collaborators: 1 to 2
- Study description expanded, about 2 words
- Notable Start date: Apr 15, 2026 to Sep 15, 2026v3
- Notable Start date: Dec 15, 2025 to Apr 15, 2026v2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (3)
Arms and interventions
Patients will receive standard of care (SOC) neoadjuvant chemotherapy and will be evaluated for enhanced clinical complete response (ecCR) after treatment. Participants who achieve an ecCR will be placed in the non-surgical arm. Participants will receive radiation therapy and routine and additional screening MRIs during follow up.
Patients will receive standard of care (SOC) neoadjuvant chemotherapy and will be evaluated for enhanced clinical complete response (ecCR) after treatment. Participants who do not achieve an ecCR will be placed in the surgical arm. Participants will undergo a lumpectomy or mastectomy, receive radiation therapy, and routine follow-up.
Drugs: Neoadjuvant Chemotherapy
Radiation: Radiation Therapy
Procedures: MRI, Breast Cancer Surgery, Biopsy, Biospecimen collection
Sites
1 site in 1 country
- Ohio State University Comprehensive Cancer CenterColumbus, Ohio, United States